Skip to content

Scott E Hemby

3 papers in the library · 21 citations · publishing 2021-2026

Papers

Sort Most recent Most cited

Development and validation of a UPLC-MS/MS method for real-time neuropharmacokinetic monitoring of iboga alkaloids in rat brain.

Journal of Pharmaceutical and Biomedical Analysis June 24, 2026 Scot Mcintosh, Isabella Maldonado, Nickalus C Smith et al.

Iboga alkaloids, including ibogaine, its primary metabolite noribogaine, and the naturally occurring congener ibogamine, have shown promise for the treatment of substance use and other neuropsychiatric disorders but are limited by cardiotoxic effects. Safer synthetic analogs, such as oxa-noribogaine, are under active development; however, validated analytical methods for quantifying these...

Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models.

Nature Communications September 20, 2024 Václav Havel, Andrew C Kruegel, Benjamin Bechand et al. 18 citations

Ibogaine and its main metabolite noribogaine provide important molecular prototypes for markedly different treatment of substance use disorders and co-morbid mental health illnesses. However, these compounds present a cardiac safety risk and a highly complex molecular mechanism. We introduce a class of iboga alkaloids - termed oxa-iboga - defined as benzofuran-containing iboga analogs and...

Novel Class of Psychedelic Iboga Alkaloids Disrupts Opioid Use

bioRxiv (Cold Spring Harbor Laboratory) July 23, 2021 Václav Havel, Andrew C Kruegel, Benjamin Bechand et al. 3 citations preprint

Abstract Substance use and related mental health epidemics are causing increasing suffering and death in diverse communities. 1,2 Despite extensive efforts focused on developing pharmacotherapies for treating substance use disorders, there is an urgent need for radically different therapeutic approaches. 3,4 Ibogaine provides an important drug prototype in this direction, as a psychoactive...